BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int 2018;38:570-80. [PMID: 28921803 DOI: 10.1111/liv.13589] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
Number Citing Articles
1 Kalia S, Nath P, Pathak M, Anand AC. Treatment of Muscle Cramps in Patients With Cirrhosis of Liver: A Systematic Review. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.10.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Danielsen KV, Hove JD, Nabilou P, Yin M, Chen J, Zhao M, Kallemose T, Teisner AS, Siebner HR, Ehman RL, Møller S, Bendtsen F. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. Liver Int 2021;41:2149-58. [PMID: 34060714 DOI: 10.1111/liv.14981] [Reference Citation Analysis]
3 Wong YJ, Kumar R, Chua YJJ, Ang TL. Long-term albumin infusion in decompensated cirrhosis: A review of current literature . World J Hepatol 2021; 13(4): 421-432 [PMID: 33959225 DOI: 10.4254/wjh.v13.i4.421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Voiosu AM, Wiese S, Goetze JP, Hartmann O, Voiosu T, Santos K, Møller S. Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis. Biomarkers 2021;:1-12. [PMID: 34964404 DOI: 10.1080/1354750X.2021.2024599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Sumarsono A, Wang J, Xie L, Chiang GC, Tielleman T, Messiah SE, Singal AG, Mufti A, Chen C, Leveno M. Prognostic Value of Hypochloremia in Critically Ill Patients With Decompensated Cirrhosis. Crit Care Med 2020;48:e1054-61. [PMID: 32947468 DOI: 10.1097/CCM.0000000000004620] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Gopi S, Mohta S, Saraya A. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort. J Clin Exp Hepatol 2021;11:443-52. [PMID: 34276151 DOI: 10.1016/j.jceh.2020.11.001] [Reference Citation Analysis]
8 Tufoni M, Baldassarre M, Zaccherini G, Antognoli A, Caraceni P. Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Curr Hepatol Rep 2020;:1-12. [PMID: 32837825 DOI: 10.1007/s11901-020-00521-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bannon L, Merdler I, Bar N, Lupu L, Banai S, Jacob G, Shacham Y. The Cardio-Hepatic Relation in STEMI. J Pers Med 2021;11:1241. [PMID: 34945713 DOI: 10.3390/jpm11121241] [Reference Citation Analysis]
10 Møller S, Cour Sibbesen E, Madsen JL, Bendtsen F. Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. Journal of Gastroenterology and Hepatology 2018;34:1093-9. [DOI: 10.1111/jgh.14470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
11 de Souza SLB, Mota GAF, Gregolin CS, do Nascimento M, Luvizotto RAM, Bazan SGZ, Sugizaki MM, Barbisan LF, Cicogna AC, do Nascimento AF. Exercise Training Attenuates Cirrhotic Cardiomyopathy. J of Cardiovasc Trans Res 2021;14:674-84. [DOI: 10.1007/s12265-020-09997-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Clément MA, Bosoi CR, Oliveira MM, Tremblay M, Bémeur C, Rose CF. Bile-duct ligation renders the brain susceptible to hypotension-induced neuronal degeneration: Implications of ammonia. J Neurochem 2021;157:561-73. [PMID: 33382098 DOI: 10.1111/jnc.15290] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang P. Drug for heart is applicable to liver: Is it possible? Journal of the Chinese Medical Association 2020;83:1057-8. [DOI: 10.1097/jcma.0000000000000452] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Bradley CR, Cox EF, Scott RA, James MW, Kaye P, Aithal GP, Francis ST, Guha IN. Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. J Hepatol. 2018;69:1015-1024. [PMID: 29886155 DOI: 10.1016/j.jhep.2018.05.037] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
15 Barloese M, Chitgar M, Hannibal J, Møller S. Pituitary adenylate cyclase-activating peptide: Potential roles in the pathophysiology and complications of cirrhosis. Liver Int 2020;40:2578-89. [PMID: 32654367 DOI: 10.1111/liv.14602] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Birg A, Lin HC, Kanagy N. Portal Venous Flow Is Increased by Jejunal but Not Colonic Hydrogen Sulfide in a Nitric Oxide-Dependent Fashion in Rats. Dig Dis Sci 2021;66:2661-8. [PMID: 32918175 DOI: 10.1007/s10620-020-06597-5] [Reference Citation Analysis]
17 Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World J Clin Cases 2021;9:9320-32. [PMID: 34877269 DOI: 10.12998/wjcc.v9.i31.9320] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Chen B, Liu J, Li Y, He X, Zhou C, Chen Y, Zheng M. Elevated D-Dimer levels correlate with the development of hepatorenal syndrome and a poor outcome in patients with cirrhosis. Scand J Gastroenterol 2022;:1-8. [PMID: 35833837 DOI: 10.1080/00365521.2022.2098051] [Reference Citation Analysis]
19 Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. United European Gastroenterol J 2019;7:529-37. [PMID: 31065370 DOI: 10.1177/2050640619825719] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
20 Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World J Gastroenterol 2019; 25(28): 3684-3703 [PMID: 31391766 DOI: 10.3748/wjg.v25.i28.3684] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
21 Isaak A, Praktiknjo M, Jansen C, Faron A, Sprinkart AM, Pieper CC, Chang J, Fimmers R, Meyer C, Dabir D, Thomas D, Trebicka J, Attenberger U, Kuetting D, Luetkens JA. Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. Radiology 2020;297:51-61. [PMID: 32808886 DOI: 10.1148/radiol.2020201057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
22 Dragičević M, Košuta I, Kruezi E, Lovrenčić MV, Mrzljak A. Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease. Medicina (Kaunas) 2020;56:E622. [PMID: 33218157 DOI: 10.3390/medicina56110622] [Reference Citation Analysis]
23 Sepehrinezhad A, Dehghanian A, Rafati A, Ketabchi F. Impact of liver damage on blood-borne variables and pulmonary hemodynamic responses to hypoxia and hyperoxia in anesthetized rats. BMC Cardiovasc Disord 2020;20:13. [PMID: 31931715 DOI: 10.1186/s12872-019-01297-z] [Reference Citation Analysis]
24 Adebayo D, Neong SF, Wong F. Ascites and Hepatorenal Syndrome. Clin Liver Dis 2019;23:659-82. [PMID: 31563217 DOI: 10.1016/j.cld.2019.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Khanam A, Kottilil S. Acute-on-Chronic Liver Failure: Pathophysiological Mechanisms and Management. Front Med (Lausanne) 2021;8:752875. [PMID: 34820395 DOI: 10.3389/fmed.2021.752875] [Reference Citation Analysis]
26 Matyas C, Haskó G, Liaudet L, Trojnar E, Pacher P. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. Nat Rev Cardiol 2021;18:117-35. [PMID: 32999450 DOI: 10.1038/s41569-020-0433-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 West J, Gow PJ, Testro A, Chapman B, Sinclair M. Exercise physiology in cirrhosis and the potential benefits of exercise interventions: A review. J Gastroenterol Hepatol 2021. [PMID: 33638197 DOI: 10.1111/jgh.15474] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wu L, Shen Y, Li F. Non-invasive diagnosis of liver fibrosis: A review of current imaging modalities. Gastroenterol Hepatol 2020;43:211-21. [PMID: 32089376 DOI: 10.1016/j.gastrohep.2019.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Li TH, Liu CW, Huang CC, Tsai YL, Huang SF, Yang YY, Tsai CY, Hou MC, Lin HC. Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. J Clin Med 2021;10:2244. [PMID: 34064207 DOI: 10.3390/jcm10112244] [Reference Citation Analysis]
30 Bernardi M, Angeli P, Claria J, Moreau R, Gines P, Jalan R, Caraceni P, Fernandez J, Gerbes AL, O'Brien AJ, Trebicka J, Thevenot T, Arroyo V. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut 2020;69:1127-38. [PMID: 32102926 DOI: 10.1136/gutjnl-2019-318843] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 36.0] [Reference Citation Analysis]
31 Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol 2019;13:293-305. [PMID: 30791777 DOI: 10.1080/17474124.2018.1555469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
32 Sharma P, Moore K, Ganger D, Grewal P, Brown RS. Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. Liver Transpl 2020;26:1328-36. [DOI: 10.1002/lt.25834] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kelderman JR, Jolink FEJ, Benjamens S, Monroy-Gonzalez AG, Pol RA, Slart RHJA. Diagnostic accuracy of myocardial perfusion imaging in patients evaluated for kidney transplantation: A systematic review and meta-analysis. J Nucl Cardiol 2021. [PMID: 33948891 DOI: 10.1007/s12350-021-02621-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Altayar O, Lisker-Melman M. Physiologic Adaptation or Cirrhotic Cardiomyopathy: It Is Time for New Definitions! J Card Fail 2019;25:173-5. [PMID: 30716399 DOI: 10.1016/j.cardfail.2019.01.013] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hu L, Su L, Dong Z, Wu Y, Lv Y, George J, Wang J. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. J Mol Med (Berl) 2019;97:423-34. [PMID: 30721324 DOI: 10.1007/s00109-019-01746-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
37 Rittig N, Aagaard NK, Villadsen GE, Sandahl TD, Jessen N, Grønbaek H, George J. Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2021;54:320-8. [PMID: 34165199 DOI: 10.1111/apt.16460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Styczynski G, Kalinowski P, Michałowski Ł, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Zieniewicz K, Tataj E, Rabczenko D, Szmigielski CA, Sinski M. Cardiac Morphology, Function, and Hemodynamics in Patients With Morbid Obesity and Nonalcoholic Steatohepatitis. J Am Heart Assoc 2021;10:e017371. [PMID: 33847141 DOI: 10.1161/JAHA.120.017371] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
39 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
40 Duarte NT, de Oliveira Godoy A, da Rocha Tenório J, Andrade NS, Franco JB, Pérez-sayáns M, Ortega KL. Prevalence of sublingual varices in patients with cirrhosis and the correlation with nitrogen compounds. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2020;129:39-44. [DOI: 10.1016/j.oooo.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Longley K, Tran T, Ho V. Cirrhotic Cardiomyopathy. Gastroenterology Insights 2021;12:76-88. [DOI: 10.3390/gastroent12010008] [Reference Citation Analysis]
42 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
43 Gowda YH, Jagtap N, Karyampudi A, Rao NP, Deepika G, Sharma M, Gupta R, Tandan M, Ramchandani M, John P, Kulkarni A, Kumar P, Bhaware B, Turpati MV, Reddy ND. Fractional Excretion of Sodium and Urea in Differentiating Acute Kidney Injury Phenotypes in Decompensated Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.09.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Ali B, Salim A, Alam A, Zuberi BF, Ali Z, Azam Z, Kamani L, Farooqi JI, Salih M, Nawaz AA, Chaudhry AA, Hashmi ZY, Siddique M. HEP-Net opinion on the management of ascites and its complications in the setting of decompensated cirrhosis in the resource constrained environment of Pakistan. Pak J Med Sci 2020;36:1117-32. [PMID: 32704299 DOI: 10.12669/pjms.36.5.2407] [Reference Citation Analysis]
45 Adebayo D, Neong SF, Wong F. Refractory ascites in liver cirrhosis. Am J Gastroenterol. 2018;. [PMID: 29973706 DOI: 10.1038/s41395-018-0185-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
46 Jagarlamudi N, Wong F. Acute kidney injury: prediction, prognostication and optimisation for liver transplant. Hepatol Int 2020;14:167-79. [DOI: 10.1007/s12072-020-10018-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
47 Hansen JD, Perri RE, Riess ML. Liver and Biliary Disease of Pregnancy and Anesthetic Implications: A Review. Anesth Analg 2021;133:80-92. [PMID: 33687174 DOI: 10.1213/ANE.0000000000005433] [Reference Citation Analysis]
48 Brunsing RL, Brown D, Almahoud H, Kono Y, Loomba R, Vodkin I, Sirlin CB, Alley MT, Vasanawala SS, Hsiao A. Quantification of the Hemodynamic Changes of Cirrhosis with Free-Breathing Self-Navigated MRI. J Magn Reson Imaging 2021;53:1410-21. [PMID: 33594733 DOI: 10.1002/jmri.27488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Sagawa E, Okubo H, Ando H, Sorin Y, Kanazawa R, Nakadera E, Fukada H, Kokubu S, Miyazaki A. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites. Journal of Pharmacological Sciences 2019;139:373-6. [DOI: 10.1016/j.jphs.2019.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zardi EM, Giorgi C, Dobrina A, Vecile E, Zardi DM. Analogies and differences between cirrhotic cardiomyopathy and hepatopulmonary syndrome. Med Res Rev 2021;41:739-53. [PMID: 33174630 DOI: 10.1002/med.21755] [Reference Citation Analysis]
51 Sabapathy DG, Desai MS. Acute Liver Failure in Children. Pediatr Clin North Am 2022;69:465-95. [PMID: 35667757 DOI: 10.1016/j.pcl.2022.02.003] [Reference Citation Analysis]
52 Møller S, Danielsen KV, Wiese S, Hove JD, Bendtsen F. An update on cirrhotic cardiomyopathy. Expert Rev Gastroenterol Hepatol 2019;13:497-505. [PMID: 30802157 DOI: 10.1080/17474124.2019.1587293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
53 Lu X, Wang Z, Yang L, Yang C, Song M. Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study. Front Cardiovasc Med 2021;8:704073. [PMID: 34291096 DOI: 10.3389/fcvm.2021.704073] [Reference Citation Analysis]
54 Kidoguchi S, Kitada K, Nakajima K, Nakano D, Ohsaki H, Kittikulsuth W, Kobara H, Masaki T, Yokoo T, Takahashi K, Titze J, Nishiyama A. Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats. Life Sci 2022;289:120192. [PMID: 34871664 DOI: 10.1016/j.lfs.2021.120192] [Reference Citation Analysis]
55 Chung HS, Woo A, Chae MS, Hong SH, Park CS, Choi JH, Jo YS. Combined B-type Natriuretic Peptide as strong predictor of short-term mortality in patients after Liver Transplantation. Int J Med Sci 2021;18:2500-9. [PMID: 34104081 DOI: 10.7150/ijms.54202] [Reference Citation Analysis]
56 Balapattabi K, Little JT, Bachelor ME, Cunningham RL, Cunningham JT. Sex Differences in the Regulation of Vasopressin and Oxytocin Secretion in Bile Duct-Ligated Rats. Neuroendocrinology 2021;111:237-48. [PMID: 32335554 DOI: 10.1159/000508104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
57 Shi Q, Xiong K, Ding B, Ye X. Clinical characteristics of cirrhosis patients with umbilical vein recanalization: A retrospective analysis. Medicine (Baltimore) 2021;100:e26774. [PMID: 34477116 DOI: 10.1097/MD.0000000000026774] [Reference Citation Analysis]
58 Di Dato F, Ranucci G, de Ville de Goyet J, Alberti D, Iorio R. Unusual Clinical Course for Untreated Malformative Biliary Atresia Infant: Is Portal Hypertension an Important Driver of Liver Fibrosis? J Pediatr Gastroenterol Nutr 2021;72:216-9. [PMID: 32925558 DOI: 10.1097/MPG.0000000000002932] [Reference Citation Analysis]
59 Wang SF, Huang YT, Huang CH, Chang SH, Lin CY. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med 2020;8:1223. [PMID: 33178755 DOI: 10.21037/atm-20-2444] [Reference Citation Analysis]
60 Juanola A, Solé C, Toapanta D, Ginès P, Solà E. Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. Clin Liver Dis 2021;25:441-60. [PMID: 33838860 DOI: 10.1016/j.cld.2021.01.011] [Reference Citation Analysis]
61 Lee DU, Fan GH, Hastie DJ, Prakasam VN, Addonizio EA, Ahern RR, Seog KJ, Karagozian R. The Clinical Impact of Cirrhosis on the Hospital Outcomes of Patients Admitted With Influenza Infection: Propensity Score Matched Analysis of 2011-2017 US Hospital Data. J Clin Exp Hepatol 2021;11:531-43. [PMID: 34511813 DOI: 10.1016/j.jceh.2021.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res 2019;52:e7809. [PMID: 30785477 DOI: 10.1590/1414-431X20187809] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
63 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
64 Shigefuku R, Iwasa M, Eguchi A, Tempaku M, Tamai Y, Suzuki T, Takei Y. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Intern Med 2021;60:3359-68. [PMID: 34719623 DOI: 10.2169/internalmedicine.7291-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sabang RL, Abu-Hishmeh M, Bodin R, Epelbaum O. Impact of Liver Transplantation on Carbon Monoxide Production as Measured by Arterial Carboxyhemoglobin Levels in Cirrhotic Patients with and without Hepatopulmonary Syndrome. Ann Transplant 2021;26:e932009. [PMID: 34518507 DOI: 10.12659/AOT.932009] [Reference Citation Analysis]